Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents
- PMID: 12201585
- DOI: 10.4269/ajtmh.2002.66.516
Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents
Abstract
The neurotoxicity of beta-arteether (AE) is related to drug accumulation in blood due to slow and prolonged absorption from the intramuscular injection sites. In this efficacy and toxicity study of AE, the traditional sesame oil vehicle was replaced with cremophore to decrease the accumulation and toxicity of AE. Dihydroartemisinin (DQHS), a more toxic and active metabolite of AE, was also analyzed. When administered at a daily dosage of 25 mg/kg for seven days, blood accumulation of AE with sesame oil (AESO) was used had a 7.5-fold higher area under the curve (AUC) (on last versus first day dosing), while AE with cremophore (AECM) had only a 1.8-fold higher AUC. Although the accumulation of AECM was greatly reduced, its total exposure level (46.29 microg x h/ml) was 2.7-fold higher than with AESO (16.92 microg x h/ml) due to a higher bioavailability of AECM (74.5%) compared with AESO (20.3%). Total exposure time (calculated at over the minimal detected neurotoxicity level of 41.32 ng/ml) of AECM was 103 hours during the whole treatment period (192 hours), which was more than one-third (37%) less than with AESO (162 hours). Similar pharmacokinetic results were also shown with the active metabolite, DQHS. Anorexia and gastrointestinal toxicity with AESO were significantly more severe than with AECM (P < 0.001). Histopathologic examination of the brain demonstrated neurotoxic changes; the AESO rat group was significantly more severe than the AECM rat group. The brain injury scores with AECM were mild to moderate (2.3-3.0), and with AESO they were moderate to severe (3.0-4.7) on day 7 and day 10, respectively. In addition, the results of a 50% cure dose (CD50) against Plasmodium berghei in mice were 34.1 mg/kg for AESO and 14.2 mg/kg for AECM, indicating a significant higher efficacy was found in the AECM animals. Toxicity and efficacy of DQHS were also dependent on its exposure time and level, which was the same as its parent drug (AE). In conclusion, following the seven-day treatment in rats, AE and DQHS exposure time and level varied based on the vehicle used. The extension of drug exposure time and the low peak level of AE and DQHS were more associated with severe neurotoxicity and lower antimalarial efficacy, whereas the high level and short exposure time of AE and DQHS resulted in higher efficacy and milder toxicity.
Similar articles
-
The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats.J Pharm Pharmacol. 1998 Feb;50(2):173-82. doi: 10.1111/j.2042-7158.1998.tb06173.x. J Pharm Pharmacol. 1998. PMID: 9530985
-
Effects of Plasmodium berghei infection on arteether metabolism and disposition.Pharmacology. 1997 May;54(5):276-84. doi: 10.1159/000139496. Pharmacology. 1997. PMID: 9380774
-
Toxicokinetic and toxicodynamic (TK/TD) evaluation to determine and predict the neurotoxicity of artemisinins.Toxicology. 2011 Jan 11;279(1-3):1-9. doi: 10.1016/j.tox.2010.09.005. Epub 2010 Sep 21. Toxicology. 2011. PMID: 20863871 Review.
-
Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe Plasmodium falciparum malaria.Am J Trop Med Hyg. 2004 Dec;71(6):723-31. Am J Trop Med Hyg. 2004. PMID: 15642961 Clinical Trial.
-
Toxicity of the antimalarial artemisinin and its dervatives.Crit Rev Toxicol. 2010 May;40(5):405-21. doi: 10.3109/10408441003610571. Crit Rev Toxicol. 2010. PMID: 20158370 Review.
Cited by
-
Dihydroartemisinin attenuates hypoxic-ischemic brain damage in neonatal rats by inhibiting oxidative stress.Mol Brain. 2022 Apr 28;15(1):36. doi: 10.1186/s13041-022-00921-y. Mol Brain. 2022. PMID: 35484595 Free PMC article.
-
Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain.Antimicrob Agents Chemother. 2011 Apr;55(4):1383-90. doi: 10.1128/AAC.01277-10. Epub 2011 Jan 10. Antimicrob Agents Chemother. 2011. PMID: 21220531 Free PMC article.
-
Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review.Malar J. 2020 Mar 14;19(1):111. doi: 10.1186/s12936-020-03184-x. Malar J. 2020. PMID: 32169086 Free PMC article. Review.
-
Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand.Malar J. 2008 Nov 6;7:233. doi: 10.1186/1475-2875-7-233. Malar J. 2008. PMID: 18986553 Free PMC article.
-
Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.Antimicrob Agents Chemother. 2004 Aug;48(8):2966-72. doi: 10.1128/AAC.48.8.2966-2972.2004. Antimicrob Agents Chemother. 2004. PMID: 15273107 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical